Loading...

Dishman Carbogen Amcis

NSEI:DCAL
Snowflake Description

Flawless balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DCAL
NSEI
₹36B
Market Cap
  1. Home
  2. IN
  3. Pharmaceuticals & Biotech
Company description

Dishman Carbogen Amcis Limited provides contract research and manufacturing services worldwide. The last earnings update was 36 days ago. More info.


Add to Portfolio Compare Print
DCAL Share Price and Events
7 Day Returns
-9.3%
NSEI:DCAL
-1.4%
IN Life Sciences
-2.7%
IN Market
1 Year Returns
-23.7%
NSEI:DCAL
25.8%
IN Life Sciences
-1.8%
IN Market
DCAL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Dishman Carbogen Amcis (DCAL) -9.3% 0.8% 6.2% -23.7% - -
IN Life Sciences -1.4% -4% -3.6% 25.8% 43.1% 126.6%
IN Market -2.7% -1.2% -0.9% -1.8% 30.5% 37.8%
1 Year Return vs Industry and Market
  • DCAL underperformed the Life Sciences industry which returned 25.8% over the past year.
  • DCAL underperformed the Market in India which returned -1.8% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Dishman Carbogen Amcis undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Dishman Carbogen Amcis to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Dishman Carbogen Amcis.

NSEI:DCAL Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 17%
Perpetual Growth Rate 10-Year IN Government Bond Rate 7.6%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NSEI:DCAL
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year IN Govt Bond Rate 7.6%
Equity Risk Premium S&P Global 8.6%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 0.99
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.99 (1 + (1- 35%) (24.84%))
1.1
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.1
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 7.55% + (1.1 * 8.6%)
17.01%

Discounted Cash Flow Calculation for NSEI:DCAL using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Dishman Carbogen Amcis is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NSEI:DCAL DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (INR, Millions) Source Present Value
Discounted (@ 17.01%)
2019 -618.00 Analyst x2 -528.15
2020 898.50 Analyst x2 656.22
2021 1,952.50 Analyst x2 1,218.69
2022 2,052.34 Est @ 5.11% 1,094.75
2023 2,172.28 Est @ 5.84% 990.26
2024 2,310.35 Est @ 6.36% 900.08
2025 2,465.47 Est @ 6.71% 820.86
2026 2,637.19 Est @ 6.96% 750.37
2027 2,825.49 Est @ 7.14% 687.06
2028 3,030.72 Est @ 7.26% 629.82
Present value of next 10 years cash flows ₹7,219.97
NSEI:DCAL DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= ₹3,030.72 × (1 + 7.55%) ÷ (17.01% – 7.55%)
₹34,446.20
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ₹34,446.20 ÷ (1 + 17.01%)10
₹7,158.33
NSEI:DCAL Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ₹7,219.97 + ₹7,158.33
₹14,378.30
Equity Value per Share
(INR)
= Total value / Shares Outstanding
= ₹14,378.30 / 161.39
₹89.09
NSEI:DCAL Discount to Share Price
Calculation Result
Value per share (INR) From above. ₹89.17
Current discount Discount to share price of ₹221.35
= -1 x (₹221.35 - ₹89.17) / ₹89.17
-148.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Dishman Carbogen Amcis is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Dishman Carbogen Amcis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Dishman Carbogen Amcis's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NSEI:DCAL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in INR ₹13.03
BSE:540701 Share Price ** BSE (2019-06-20) in INR ₹221.15
India Life Sciences Industry PE Ratio Median Figure of 7 Publicly-Listed Life Sciences Companies 30.28x
India Market PE Ratio Median Figure of 2,823 Publicly-Listed Companies 15.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Dishman Carbogen Amcis.

NSEI:DCAL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BSE:540701 Share Price ÷ EPS (both in INR)

= 221.15 ÷ 13.03

16.97x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dishman Carbogen Amcis is good value based on earnings compared to the IN Life Sciences industry average.
  • Dishman Carbogen Amcis is overvalued based on earnings compared to the India market.
Price based on expected Growth
Does Dishman Carbogen Amcis's expected growth come at a high price?
Raw Data
NSEI:DCAL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 16.97x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
20.5%per year
Asia Life Sciences Industry PEG Ratio Median Figure of 6 Publicly-Listed Life Sciences Companies 2.05x
India Market PEG Ratio Median Figure of 524 Publicly-Listed Companies 1.32x

*Line of best fit is calculated by linear regression .

NSEI:DCAL PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 16.97x ÷ 20.5%

0.83x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dishman Carbogen Amcis is good value based on expected growth next year.
Price based on value of assets
What value do investors place on Dishman Carbogen Amcis's assets?
Raw Data
NSEI:DCAL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in INR ₹333.58
BSE:540701 Share Price * BSE (2019-06-20) in INR ₹221.15
India Life Sciences Industry PB Ratio Median Figure of 10 Publicly-Listed Life Sciences Companies 1.93x
India Market PB Ratio Median Figure of 3,653 Publicly-Listed Companies 0.98x
NSEI:DCAL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BSE:540701 Share Price ÷ Book Value per Share (both in INR)

= 221.15 ÷ 333.58

0.66x

* Primary Listing of Dishman Carbogen Amcis.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dishman Carbogen Amcis is good value based on assets compared to the IN Life Sciences industry average.
X
Value checks
We assess Dishman Carbogen Amcis's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Dishman Carbogen Amcis has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Dishman Carbogen Amcis expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
20.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Dishman Carbogen Amcis expected to grow at an attractive rate?
  • Dishman Carbogen Amcis's earnings growth is expected to exceed the low risk savings rate of 7.6%.
Growth vs Market Checks
  • Dishman Carbogen Amcis's earnings growth is expected to exceed the India market average.
  • Dishman Carbogen Amcis's revenue growth is positive but not above the India market average.
Annual Growth Rates Comparison
Raw Data
NSEI:DCAL Future Growth Rates Data Sources
Data Point Source Value (per year)
NSEI:DCAL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 20.5%
NSEI:DCAL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 9%
India Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 17.2%
Asia Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 23.6%
India Market Earnings Growth Rate Market Cap Weighted Average 16.7%
India Market Revenue Growth Rate Market Cap Weighted Average 9.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NSEI:DCAL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in INR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NSEI:DCAL Future Estimates Data
Date (Data in INR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-03-31 25,128 4,716 3,155 7
2020-03-31 22,371 4,815 2,551 7
NSEI:DCAL Past Financials Data
Date (Data in INR Millions) Revenue Cash Flow Net Income *
2019-03-31 21,124 2,103
2018-12-31 18,924 1,862
2018-09-30 18,745 1,768
2018-06-30 18,826 1,812
2018-03-31 17,230 2,264 1,546
2017-12-31 17,854 1,537
2017-09-30 16,840 1,383
2017-06-30 16,778 1,282
2017-03-31 17,194 3,026 1,454
2016-12-31 12,038 953

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Dishman Carbogen Amcis's earnings are expected to grow significantly at over 20% yearly.
  • Dishman Carbogen Amcis's revenue is expected to grow by 9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NSEI:DCAL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Dishman Carbogen Amcis Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:DCAL Future Estimates Data
Date (Data in INR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-03-31 19.51 24.70 15.20 6.00
2020-03-31 15.75 18.80 13.60 6.00
NSEI:DCAL Past Financials Data
Date (Data in INR Millions) EPS *
2019-03-31 13.03
2018-12-31 11.53
2018-09-30 10.94
2018-06-30 11.22
2018-03-31 9.58
2017-12-31 9.53
2017-09-30 8.57
2017-06-30 7.94
2017-03-31 9.01
2016-12-31 7.85

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Dishman Carbogen Amcis is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Dishman Carbogen Amcis's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Asia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Dishman Carbogen Amcis has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Dishman Carbogen Amcis performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Dishman Carbogen Amcis's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Dishman Carbogen Amcis has delivered over 20% year on year earnings growth in the past 5 years.
  • Dishman Carbogen Amcis's 1-year earnings growth is less than its 5-year average (36.1% vs 39.5%)
  • Dishman Carbogen Amcis's earnings growth has not exceeded the IN Life Sciences industry average in the past year (36.1% vs 54%).
Earnings and Revenue History
Dishman Carbogen Amcis's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Dishman Carbogen Amcis Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:DCAL Past Revenue, Cash Flow and Net Income Data
Date (Data in INR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 21,124.20 2,103.30 7,146.40
2018-12-31 18,923.90 1,861.50 7,331.20
2018-09-30 18,745.20 1,767.90 7,131.70
2018-06-30 18,826.30 1,812.00 6,541.20
2018-03-31 17,229.80 1,545.70 6,766.10
2017-12-31 17,854.00 1,537.10 6,843.70
2017-09-30 16,839.70 1,382.80 6,568.10
2017-06-30 16,778.40 1,281.80 5,943.70
2017-03-31 17,193.70 1,454.30 6,495.90
2016-12-31 12,038.42 953.16 4,239.92 -35.00
2016-03-31 68.12 8.92 50.93
2015-03-31 -4.97 0.04
2014-03-31 -1.36 0.03
2013-03-31 0.21 0.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Dishman Carbogen Amcis has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Dishman Carbogen Amcis used its assets less efficiently than the IN Life Sciences industry average last year based on Return on Assets.
  • Dishman Carbogen Amcis's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Dishman Carbogen Amcis's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Dishman Carbogen Amcis has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Dishman Carbogen Amcis's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Dishman Carbogen Amcis's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Dishman Carbogen Amcis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Dishman Carbogen Amcis's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Dishman Carbogen Amcis's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Dishman Carbogen Amcis Company Filings, last reported 2 months ago.

NSEI:DCAL Past Debt and Equity Data
Date (Data in INR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 53,790.90 8,825.10 1,153.90
2018-12-31 53,389.60 11,369.80 2,291.90
2018-09-30 53,389.60 11,369.80 2,291.90
2018-06-30 51,073.30 9,182.90 1,878.40
2018-03-31 51,073.30 10,948.30 1,598.70
2017-12-31 48,854.00 9,510.00 1,782.30
2017-09-30 48,854.00 9,510.00 1,782.30
2017-06-30 48,139.80 8,940.40 2,327.40
2017-03-31 48,139.80 9,497.10 586.10
2016-12-31
2016-03-31 3.28 89.83 5.95
2015-03-31 -5.64 103.10 0.15
2014-03-31 -0.68 121.24 0.28
2013-03-31 0.68 95.57 0.36
  • Dishman Carbogen Amcis's level of debt (16.4%) compared to net worth is satisfactory (less than 40%).
  • Dishman Carbogen Amcis had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
  • Debt is well covered by operating cash flow (25.7%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 6.5x coverage).
X
Financial health checks
We assess Dishman Carbogen Amcis's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Dishman Carbogen Amcis has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Dishman Carbogen Amcis's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.09%
Current annual income from Dishman Carbogen Amcis dividends. Estimated to be 0.78% next year.
If you bought ₹2,000 of Dishman Carbogen Amcis shares you are expected to receive ₹2 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Dishman Carbogen Amcis's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.54%).
  • Dishman Carbogen Amcis's dividend is below the markets top 25% of dividend payers in India (2.08%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NSEI:DCAL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Asia Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 0.8%
India Market Average Dividend Yield Market Cap Weighted Average of 1450 Stocks 1.4%
India Minimum Threshold Dividend Yield 10th Percentile 0.3%
India Bottom 25% Dividend Yield 25th Percentile 0.5%
India Top 25% Dividend Yield 75th Percentile 2.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NSEI:DCAL Future Dividends Estimate Data
Date (Data in ₹) Dividend per Share (annual) Avg. No. Analysts
2021-03-31 1.90 2.00
2020-03-31 1.55 2.00
NSEI:DCAL Past Annualized Dividends Data
Date (Data in ₹) Dividend per share (annual) Avg. Yield (%)
2019-05-15 0.200 0.086
2019-01-23 0.000 0.000
2018-11-01 0.000 0.000
2018-08-27 0.000 0.000

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dishman Carbogen Amcis is not paying a notable dividend for India, therefore no need to check if the payments are stable.
  • Dishman Carbogen Amcis is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Dishman Carbogen Amcis's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Dishman Carbogen Amcis's dividends as it is not paying a notable one for India.
Future Payout to shareholders
  • Dividends after 3 years are expected to be thoroughly covered by earnings (10.2x coverage).
X
Income/ dividend checks
We assess Dishman Carbogen Amcis's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Dishman Carbogen Amcis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Dishman Carbogen Amcis has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Dishman Carbogen Amcis's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Arpit Vyas
COMPENSATION ₹12,500,000
AGE 32
CEO Bio

Mr. Arpit J. Vyas has been Group Managing Director of Dishman Carbogen Amcis Limited since November 28, 2018 and as its Director since April 7, 2012. He served as Chief Financial Officer and Managing Director of Dishman Carbogen Amcis Limited from March 17, 2017 to November 28, 2018. Mr. Vyas has been Global Managing Director of Dishman Pharmaceuticals and Chemicals Ltd. since November 28, 2018. He served as the Managing Director of Dishman Pharmaceuticals and Chemicals Ltd. from May 28, 2013 to November 28, 2018 and its Chief Financial Officer from July 17, 2015 to November 28, 2018. Mr. Vyas has been a Whole-Time Director of Dishman Pharmaceuticals and Chemicals Ltd. since June 1, 2009. Mr. Vyas serves as a Director of Schutz Dishman Biotech Limited, Azafran Innovacion Limited and Dishman Care Limited. He has experience of handling Marketing of various herbal cosmetic products of Azafran Innovacion Pvt. Ltd., since last two years, in which he holds Directorship. Mr. Vyas has completed his education from University of Aston, Birmingham for degree in Chemical Engineering in 2009.

CEO Compensation
  • Arpit's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Arpit's remuneration is lower than average for companies of similar size in India.
Management Team

Janmejay Vyas

TITLE
Chairman of the Board
COMPENSATION
₹27M
AGE
67

Arpit Vyas

TITLE
Group MD & Director
COMPENSATION
₹13M
AGE
32

Mark Griffiths

TITLE
Director of Global Marketing & Strategy and Director
AGE
54

Shrima Dave

TITLE
Compliance Officer & Company Secretary
COMPENSATION
₹633K

Deohooti Vyas

TITLE
Whole Time Director
COMPENSATION
₹13M
AGE
67
TENURE
2.3 yrs

Harshil Dalal

TITLE
Global Chief Financial Officer
TENURE
0.6 yrs

Alan Fischer

TITLE
Global Chief Information Officer

Dharmesh Desai

TITLE
DGM of Legal & Secretarial

Dieter Thueer

TITLE
Global Head of Human Resources

Martin Schneider

TITLE
Global Chief Quality Officer
AGE
59
Board of Directors Tenure

Average tenure and age of the Dishman Carbogen Amcis board of directors in years:

2.3
Average Tenure
66
Average Age
  • The average tenure for the Dishman Carbogen Amcis board of directors is less than 3 years, this suggests a new board.
Board of Directors

Janmejay Vyas

TITLE
Chairman of the Board
COMPENSATION
₹27M
AGE
67

Arpit Vyas

TITLE
Group MD & Director
COMPENSATION
₹13M
AGE
32
TENURE
7.2 yrs

Mark Griffiths

TITLE
Director of Global Marketing & Strategy and Director
AGE
54

Deohooti Vyas

TITLE
Whole Time Director
COMPENSATION
₹13M
AGE
67
TENURE
2.3 yrs

Sanjay Majmudar

TITLE
Independent Director
COMPENSATION
₹2M
AGE
55
TENURE
2.3 yrs

Ashok Gandhi

TITLE
Independent Director
COMPENSATION
₹1M
AGE
79
TENURE
2.3 yrs

Subir Das

TITLE
Independent Director
COMPENSATION
₹1M
AGE
65
TENURE
2.3 yrs

Rajendra Shah

TITLE
Independent Director
COMPENSATION
₹830K
AGE
70

Maitri Mehta

TITLE
Additional Independent Director
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₹) Value (₹)
X
Management checks
We assess Dishman Carbogen Amcis's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Dishman Carbogen Amcis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

If You Had Bought Dishman Carbogen Amcis (NSE:DCAL) Stock A Year Ago, You'd Be Sitting On A 17% Loss, Today

While not a mind-blowing move, it is good to see that the Dishman Carbogen Amcis Limited (NSE:DCAL) share price has gained 22% in the last three months. … See our latest analysis for Dishman Carbogen Amcis To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. … Even though the Dishman Carbogen Amcis share price is down over the year, its EPS actually improved.

Simply Wall St -

Why Dishman Carbogen Amcis Limited's (NSE:DCAL) High P/E Ratio Isn't Necessarily A Bad Thing

We'll apply a basic P/E ratio analysis to Dishman Carbogen Amcis Limited's (NSE:DCAL), to help you decide if the stock is worth further research. … What is Dishman Carbogen Amcis's P/E ratio? … See our latest analysis for Dishman Carbogen Amcis?

Simply Wall St -

These Fundamentals Make Dishman Carbogen Amcis Limited (NSE:DCAL) Truly Worth Looking At

Building up an investment case requires looking at a stock holistically. … Today I've chosen to put the spotlight on Dishman Carbogen Amcis Limited (NSE:DCAL) due to its excellent fundamentals in more than one area.

Simply Wall St -

Investors Who Bought Dishman Carbogen Amcis (NSE:DCAL) Shares A Year Ago Are Now Down 33%

Unfortunately the Dishman Carbogen Amcis Limited (NSE:DCAL) share price slid 33% over twelve months. … Even though the Dishman Carbogen Amcis share price is down over the year, its EPS actually improved. … Dishman Carbogen Amcis managed to grow revenue over the last year, which is usually a real positive.

Simply Wall St -

Does Dishman Carbogen Amcis Limited's (NSE:DCAL) P/E Ratio Signal A Buying Opportunity?

We'll look at Dishman Carbogen Amcis Limited's (NSE:DCAL) P/E ratio and reflect on what it tells us about the company's share price. … Dishman Carbogen Amcis has a P/E ratio of 17.86, based on the last twelve months. … How Do You Calculate Dishman Carbogen Amcis's P/E Ratio

Simply Wall St -

Dishman Carbogen Amcis Limited (NSE:DCAL): The Best Of Both Worlds

Attractive stocks have exceptional fundamentals. … In the case of Dishman Carbogen Amcis Limited (NSE:DCAL), there's

Simply Wall St -

Could Dishman Carbogen Amcis Limited's (NSE:DCAL) Investor Composition Influence The Stock Price?

Every investor in Dishman Carbogen Amcis Limited (NSE:DCAL) should be aware of the most powerful shareholder groups. … Dishman Carbogen Amcis is a smaller company with a market capitalization of ₹37b, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company.

Simply Wall St -

Is It Too Late To Buy Dishman Carbogen Amcis Limited (NSE:DCAL) At Its November Price?

Dishman Carbogen Amcis Limited (NSE:DCAL) is considered a high growth stock. … Check out our latest analysis for Dishman Carbogen Amcis? … If you are bullish about Dishman Carbogen Amcis's growth potential then you are certainly not alone

Simply Wall St -

Read This Before You Buy Dishman Carbogen Amcis Limited (NSE:DCAL) Because Of Its P/E Ratio

We'll show how you can use Dishman Carbogen Amcis Limited's (NSE:DCAL) P/E ratio to inform your assessment of the investment opportunity. … Dishman Carbogen Amcis has a price to earnings ratio of 20.5, based on the last twelve months. … How Do You Calculate Dishman Carbogen Amcis's P/E Ratio

Simply Wall St -

Who Are The Top Investors In Dishman Carbogen Amcis Limited (NSE:DCAL)?

I am going to take a deep dive into Dishman Carbogen Amcis Limited’s (NSE:DCAL) most recent ownership structure, not a frequent subject of discussion among individual investors. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment. … View our latest analysis for Dishman Carbogen Amcis

Simply Wall St -

Company Info

Description

Dishman Carbogen Amcis Limited provides contract research and manufacturing services worldwide. It manufactures and supplies marketable molecules, such as bulk drugs, intermediates, quaternary ammonium compounds, specialty chemicals, vitamins and chemicals, and disinfectants. The company was incorporated in 2007 and is based in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Bhadra- Raj Holdings Pvt. Ltd.

Details
Name: Dishman Carbogen Amcis Limited
DCAL
Exchange: NSEI
Founded: 2007
₹35,530,948,980
161,394,272
Website: http://www.dishmangroup.com
Address: Dishman Carbogen Amcis Limited
Dishman Corporate House,
Opp. Jayantilal Park BRTS Bus Stop,
Ahmedabad,
Gujarat, 380058,
India
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BSE 540701 Equity Shares Mumbai Stock Exchange IN INR 21. Sep 2017
NSEI DCAL Equity Shares National Stock Exchange of India IN INR 21. Sep 2017
Number of employees
Current staff
Staff numbers
0
Dishman Carbogen Amcis employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/20 12:57
End of day share price update: 2019/06/20 00:00
Last estimates confirmation: 2019/06/10
Last earnings filing: 2019/05/15
Last earnings reported: 2019/03/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.